Leipzig Tourismus und Marketing GmbH
5
Pioneering Heart Surgery and Medical Congresses in Leipzig
One document
more
Stories about Medizinische Behandlung
- 3
EU Provides 1 Mio. to Researchers to Advance Personalised Oncology
One documentmore - 2
Press release : People with Parkinson’s experience variations in effects of oral medicines, but lack advice, international survey reveals
One documentmore Press release: STADA and Xbrane launch ranibizumab to support patient access in Europe
STADA and Xbrane launch ranibizumab to support patient access in Europe - Ranibizumab biosimilar is being launched in major European markets - Ranibizumab is the first product brought to market through a strategic collaboration between STADA and Xbrane, marking Xbrane’s first commercial launch and ...
One documentmore- 5
Press Release - hubergroup India expands its support for rural healthcare
One documentmore Free Access to Cancer Research Services - canSERV 1st Call for Proposals
One documentmorePress release: EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab) - Partners Alvotech and STADA have marketing authorization application (MAA) for ustekinumab accepted for filing by the European Medicines Agency (EMA) ...
One documentmorePress release: STADA and Xbrane secure EU approval for Ximluci® (ranibizumab) biosimilar referencing Lucentis®
STADA and Xbrane secure EU approval for Ximluci® (ranibizumab) biosimilar referencing Lucentis® - European Commission grants pan-EU marketing authorization for Ximluci® biosimilar referencing Lucentis® (ranibizumab) - Paves way for European ...
One documentmorePress release: STADA sets standard in Specialty by launching the first medicine authorized in the EU for treating rare kidney disease
STADA sets standard in Specialty by launching the first medicine authorized in the EU for treating rare kidney disease - Germany is STADA’s lead launch market for EU’s first authorized treatment for a rare kidney disease immunoglobulin A ...
One documentmorePress release: Strong in-market performance leads STADA to double-digit growth
Strong in-market performance leads STADA to double-digit growth - Continued strong organic market-share gains across key European markets, supported by several launches - Adjusted Group sales advance by 15% while adjusted EBITDA improve by 23% in first half of 2022 - STADA CEO Peter Goldschmidt: “In ...
One documentmorePress release: STADA welcomes EU approval of Kinpeygo® for adults with primary IgA nephropathy
STADA welcomes EU approval of Kinpeygo® for adults with primary IgA nephropathy - The European Commission (EC) has granted conditional marketing authorization for Kinpeygo® for the treatment of primary immunoglobulin A (IgA) nephropathy (IgAN) in adults at risk of rapid disease progression with a ...
One documentmore- 3
Sysmex Europe SE and Sysmex Inostics GmbH launch two CE-IVD certified Plasma-SeqSensei™ liquid biopsy kits: Solid Cancer IVD Kit and Breast Cancer IVD Kit
One documentmore Press release: STADA set to expand Specialty portfolio after positive CHMP opinion on Kinpeygo orphan medicine for IgA nephropathy
STADA set to expand Specialty portfolio after positive CHMP opinion on KinpeygoTM orphan medicine for IgA nephropathy - CHMP within the European Medicines Agency issues positive opinion on KinpeygoTM, a novel oral formulation of budesonide, for ...
One documentmore- 4
RTL Donation Marathon: Einhell offers support to children suffering from cancer
One documentmore - 2
Lindis Biotech develops immunotherapy against bladder cancer
One documentmore - 3
World Cancer Day: Start-ups at the IZB develop innovative cancer drugs and diagnostic tools
One documentmore Inspirational talks form SIRION Biotech, CLS Behring and the German Accelerator at the 13th Biotech Press Lounge at the IZB
One documentmoreThe development of a combination drug for immunotherapy and trends of the VC and pharmaceutical branch were introduced at the IZB
One documentmoreHigh investor density at the Pitch Day hosted by IZB
One documentmore
1